Articles > Cencora, Inc. (COR) Q2 2026 Earnings Disappoint, Stock Falls
- Cencora Inc. (COR) reports lower-than-expected Q2 earnings and revenue
- Despite missing estimates, the company raises its fiscal 2026 EPS outlook
- Quarterly earnings come in at $4.75 per share, below the Zacks Consensus Estimate
- Cencora raises annual profit forecast, banking on steady demand for specialty medicines
- Revenue increases by 3.8% year-over-year to $78.4 billion in fiscal 2026 Q2
Cencora, Inc. (COR) faced a decline in its stock price on Wednesday as the company released its fiscal 2026 second-quarter results, which fell short of expectations and led to a downward revision of its annual guidance. Despite raising its fiscal 2026 earnings per share (EPS) outlook, Cencora's shares witnessed a decrease following the disappointing financial results.
The pharmaceutical company, Cencora (COR), reported a quarterly earnings per share of $4.75, missing the Zacks Consensus Estimate of $4.80 per share. This was a decrease compared to the $4.42 per share earnings reported a year ago. Although the second-quarter results did not meet market expectations, Cencora remains optimistic about its profitability in the coming months.
Despite falling short of Wall Street estimates with its second-quarter results, Cencora increased its annual profit forecast, highlighting its confidence in the demand for specialty medicines. The company's revenue for the fiscal 2026 second quarter saw a 3.8% increase year-over-year, reaching $78.4 billion. Additionally, Cencora's adjusted diluted EPS, a non-GAAP financial measure, was reported at $8.40 for the second quarter of fiscal 2026, showing substantial growth compared to the $3.68 EPS in the same period the previous year.
Cencora, Inc. (COR) experienced a drop in its stock price after reporting lower-than-expected second-quarter earnings and revenues. Despite the disappointing results, the company raised its fiscal 2026 EPS outlook and annual profit forecast, indicating its confidence in future growth and success in the pharmaceutical industry.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Cencora, Inc. (COR) Q2 2026 Earnings Disappoint, Stock Falls
By KlickAnalytics Data Insights | May 6, 2026 08:06PM ET
Key Points
- Cencora Inc. (COR) reports lower-than-expected Q2 earnings and revenue
- Despite missing estimates, the company raises its fiscal 2026 EPS outlook
- Quarterly earnings come in at $4.75 per share, below the Zacks Consensus Estimate
- Cencora raises annual profit forecast, banking on steady demand for specialty medicines
- Revenue increases by 3.8% year-over-year to $78.4 billion in fiscal 2026 Q2
Cencora, Inc. (COR) faced a decline in its stock price on Wednesday as the company released its fiscal 2026 second-quarter results, which fell short of expectations and led to a downward revision of its annual guidance. Despite raising its fiscal 2026 earnings per share (EPS) outlook, Cencora's shares witnessed a decrease following the disappointing financial results.
The pharmaceutical company, Cencora (COR), reported a quarterly earnings per share of $4.75, missing the Zacks Consensus Estimate of $4.80 per share. This was a decrease compared to the $4.42 per share earnings reported a year ago. Although the second-quarter results did not meet market expectations, Cencora remains optimistic about its profitability in the coming months.
Despite falling short of Wall Street estimates with its second-quarter results, Cencora increased its annual profit forecast, highlighting its confidence in the demand for specialty medicines. The company's revenue for the fiscal 2026 second quarter saw a 3.8% increase year-over-year, reaching $78.4 billion. Additionally, Cencora's adjusted diluted EPS, a non-GAAP financial measure, was reported at $8.40 for the second quarter of fiscal 2026, showing substantial growth compared to the $3.68 EPS in the same period the previous year.
Cencora, Inc. (COR) experienced a drop in its stock price after reporting lower-than-expected second-quarter earnings and revenues. Despite the disappointing results, the company raised its fiscal 2026 EPS outlook and annual profit forecast, indicating its confidence in future growth and success in the pharmaceutical industry.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.